anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1,153,022. Polymer latices. MONSANTO CO. 20 March, 1967 [21 March, 1966], No. 12870/67. Heading C3P. Polymer latices, suitable for opacifying products such as liquid detergents, hair creams and floor waxes, comprise the polymerization product of (a) an α,#-ethylenically unsaturated carboxylic acid, (b) an at least diolefinically unsaturated compound and (c) a vinylidene monomer, wherein the polymer particles of the latex comprise from 60-90% by weight of an inner polymer composition and 10-40% by weight of an outer polymer composition orientated to the surface of the particles, the outer polymer composition comprising from 24-70 mol. per cent of component (a), from 0À6-3À0 mol. per cent of component (b) and the balance of the outer composition being component (c). Preferably, the inner polymer composition comprises component (c) alone, or together with oomponent(a) and/or component (b). The lances can be obtained by polymerizing, in aqueous emulsion, a monomeric material capable of yielding the inner polymer composition and subsequently polymerizing a monomeric material capable of yielding the outer polymer composition. The process may be effected batchwise in two separate steps, or continuously wherein the composition of the monomer charge is suitably adjusted at appropriate stages in the process. If desired, a homogeneous product can be obtained by making the inner polymer composition the same as the outer polymer composition. In examples the inner polymer compositions comprise (i) styrene-methacrylic acid, (ii) styrene, (iii) styrene-acrylonitrile, (iv) methyl methacrylate, (v) styrene-methyl acrylate, (vi) styrene dibutyl fumarate and (vii) styrenemethacrylic acid-divinyl benzene; and the outer polymer compositions comprise (i) styrenemethacrylic acid-divinyl benzene, (ii) methyl methacrylate-methyacrylic acid-ethylene dimethacrylate, (iii) styrene-methacrylic acidethylene dimethacrylate and (iv) styreneacrylic acid-diallyl fumarate. The monomers of these compositions are polymerized in aqueous emulsion containing sodium alkylbenzene sulphonate, tetrasodium pyrophosphate and potassium persulphate, and when polymerization is completed the latex is neutralized by addition of NH 4 OH.
The attention control arm (N=300) will receive standard doula care and the same number of telephone or video-delivered sessions and will last the same amount of time on general postpartum health topics not related to CV health or depression. Attention control participants will not receive doula-initiated outreach during the first 7 days.
The present invention relates to a system and a method for determining a stroke based on a voice analysis. According to the present invention, voice data of subjects are collected to extract and analyze voice onset times to determine stroke patients based on voices. The system for determining a stroke generates and collects voice data from test subjects reading a predetermined word that includes a plosive sound. The system for determining a stroke extracts and calculates voice onset times from the voice data to calculate probability parameters for the voice onset times of each of a normal group and a stroke patient group. The system for determining a stroke uses a set of probability parameters to determine an integration section, and calculates probabilities of being in the normal group and the stroke patient group. The system for determining a stroke applies the calculated probabilities to the Bayes theorem to determine whether the subjects are stroke patients.
Blood and cerebrospinal fluid samples will be subjected to the procedures required for the isolation of the different components immediately after the withdrawal. Subsequently, the levels of microRNAs, cytokines, chemokines, cell growth factors, neuronal damage markers (tau, phosphorylated and truncated tau, neurofilaments) and mitochondrial (lactate) and free d-amino acids (Objective 1) will be determined. Furthermore, synaptic alterations will be evaluated in the ex vivo chimeric model of MS, using the patch-clamp technique (Objective 2). Genotyping studies will be conducted in order to identify single nucleotide polymorphisms (SNPs) in coding and / or regulating regions of genes (microRNAs or proteins) involved in alterations of the synaptic transmission of MS and its murine experimental model (i.e. SLC1A3, NGFB, PDGFA, etc.), which correlate with specific clinical parameters (i.e. EDSS, BREMS, disease progression index, MS type, disease activity, etc.) and with the levels of potential biomarkers identified
PURPOSE:To produce a make-up cosmetic for masking the pores, chapped skin, wrinkles, etc., by compounding granular silicone having slipperiness, spreadability and adhesivity and containing a silicone oil as an oil having high affinity to the skin. CONSTITUTION:This make-up cosmetic is produced by compounding a specific amount of a granular silicone containing a silicone oil. The amount of the granular silicone is preferably 0.5-30 pts.wt., especially 3-15 pts.wt. The ratio of (titanium oxide+zinc oxide)/(granular silicone) in the cosmetic is preferably <2.5. The make-up cosmetic is preferably further incorporated with 0.5-20 pts.wt. of a polyhydric alcohol (e.g. propylene glycol, dipropylene glycol, 1,3- butylene glycol or glycerol) and the ratio of the polyhydric alcohol to the total amount of the oil is preferably >0.2.
The Surgery + BCG group will first have a complete resection (surgical removal) of all known disease, if possible. After recovery from surgery, two doses of BCG will be given two weeks apart. Each dose is given as 8 separate injections into the skin (called intradermal injections).
The invention relates to a modern Chinese medicine compound preparation with golden pricklyash peel and zedoary, and a preparation method thereof, and provides a pure Chinese medicine modern compound preparation. The preparation is prepared by combining extract of three Chinese medicine materials such as pricklyash peel and grubs. One prescription has four dosage forms. A processing method is divided into four processes, namely a process of purchasing and preparing materials, a process of processing grubs, a process of mutually dissolving the materials and manufacturing capsules for finished materials and a process of separately packaging finished medicine. The prescription is scientific and novel in compatibility of medicines. The preparation is bright and miscible, and the guarantee period of the preparation can be as long as more than five years. The preparation has the functions of removing blood stasis, reducing blood lipid, dissolving thrombus, diminishing inflammation, sterilizing, eliminating dampness, reducing phlegm, relieving cough and asthma, protecting liver, promoting digestion, easing pain, relieving itching, recovering pulse, preventing prostration, expelling toxicity and removing tumors, can effectively relieve various types of cancer, can effectively treat epigastralgia, cardiovascular and cerebrovascular diseases, acute/chronic gastroenteritis, chronic pharyngitis, bronchitis, oral inflammation, viral hepatitis, rheumatoid arthritis, silicosis and female genital inflammation, and can effectively relieve the sequelae of presbycardia and cardiovascular and cerebrovascular diseases.
FIELD: pharmaceuticals.SUBSTANCE: group of inventions relates to the area of medicine and pharmaceuticals. Objects 1 and 2 constitute a composition containing a) a compound selected from maltose, glycerol, amino acid, oligopeptide or a mixture thereof, at a content of 5 to 75% wt. relative to the total weight of components a) to d); b) glucose at a content of less than 1/2 of the content of component a) and at a total content of less than 5% wt. relative to the total weight of components a) to d); c) alpha-glucan molecules with DP 3 (polymerisation degree) and DP 4 at a total content of less than 1/2 of the content of component a); d) alpha-glucan molecules with a DP of greater than 4 at a content providing 100% wt. combined with components a), b) and c), and a liquid water composition for peritoneal dialysis. Objects 3 and 4 are methods of synthesis of the composition. Objects 5 and 6 are a container and a kit for an osmotically active composition containing the composition.EFFECT: higher osmolality of the composition according to the invention than that of a composition containing icodextrin, at a lower concentration of carbohydrate; increased total ultrafiltration acceptable during short dialysis cycles; content of components with high molecular weight at a concentration sufficient to maintain a positive osmotic pressure during the entire cycle.22 cl, 18 tbl, 5 ex
Participants randomized to receive a single, peripheral IV infusion of UX053 or Placebo every 2 weeks (Q2W) for 5 doses. Participants will also receive premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
Duloxetine twice daily orally Days 1 - 13. AVP-786 twice daily orally Days 6 - 13.
Following the baseline survey, participants in the assessment only group will be texted again 3 and 6 months later to complete follow up assessments. Following the end of the 6-month follow-up, participants will be offered an opportunity to complete the TIPS-BI without peer coach follow-up.
Noise-induced hearing loss (NIHL) is a common sensorineural hearing impairment that lacks U.S. Food and Drug Administration-approved drugs. To fill the gap in effective screening models, we used an in silico transcriptome-based drug screening approach, identifying 22 biological pathways and 64 potential small molecule treatments for NIHL. Two of these, afatinib and zorifertinib [epidermal growth factor receptor (EGFR) inhibitors], showed efficacy in zebrafish and mouse models. Further tests with EGFR knockout mice and EGF-morpholino zebrafish confirmed their protective role against NIHL. Molecular studies in mice highlighted EGFR's crucial involvement in NIHL and the protective effect of zorifertinib. When given orally, zorifertinib was found in the perilymph with favorable pharmacokinetics. In addition, zorifertinib combined with AZD5438 (a cyclin-dependent kinase 2 inhibitor) synergistically prevented NIHL in zebrafish. Our results underscore the potential for in silico transcriptome-based drug screening in diseases lacking efficient models and suggest EGFR inhibitors as potential treatments for NIHL, meriting clinical trials.
Single injection of Triamcinolone Hexacetonide (TH): 1 milliliter (mL) dose of 20 mg/ml TH. Manufactured by IntraPharm.
Disclosed is a carrier that can deliver a drug with excellent stability. Further disclosed are a method for producing same and applications of same. Membrane vesicles are used as a carrier for delivering a drug. Membrane vesicles encapsulating the aforementioned drug can be obtained by means of introducing the aforementioned drug into membrane-vesicle-producing cells, culturing the cells, and then collecting membrane vesicles produced by the aforementioned cells. These membrane vesicles are used as a carrier containing the aforementioned drug. Exosomes, for example, can be cited as the aforementioned membrane vesicles. A nucleic acid drug such as siRNA or miRNA, for example, can be cited as the aforementioned drug.
Personalized cancer vaccines based on resected tumors from patients is promising to address tumor heterogeneity to inhibit tumor recurrence or metastasis. However, it remains challenge to elicit immune activation due to the weak immunogenicity of autologous tumor antigens. Here, a hybrid membrane cancer vaccine is successfully constructed by membrane fusion to enhance adaptive immune response and amplify personalized immunotherapy, which formed a codelivery system for autologous tumor antigens and immune adjuvants. Briefly, the functional hybrid vesicles (HM-NPs) are formed by hybridizing ginseng-derived extracellular vesicles-like particles (G-EVLPs) with the membrane originated from the resected autologous tumors. The introduction of G-EVLPs can enhance the phagocytosis of autologous tumor antigens by dendritic cells (DCs) and facilitate DCs maturation through TLR4, ultimately activating tumor-specific cytotoxic T lymphocytes (CTLs). HM-NPs can indeed strengthen specific immune responses to suppress tumors recurrence and metastasis including subcutaneous tumors and orthotopic tumors. Furthermore, a long-term immune protection can be obtained after vaccinating with HM-NPs, and prolonging the survival of animals. Overall, this personalized hybrid autologous tumor vaccine based on G-EVLPs provides the possibility of mitigating tumor recurrence and metastasis after surgery while maintaining good biocompatibility.
A protocol containing yoga-based breathing exercises will be used. The audio recording of this breathing exercise protocol will be uploaded to the video. After verbal information is given about how to do the exercise, the patient will be listened to the audio recording video and will be explained how to do it in practice. Then, the patient will be placed in a comfortable position by wearing headphones and will be allowed to exercise. The patient will be asked to do yoga-based exercise twice a day, the night before the surgery, once in the morning and once in the evening before going to bed for 3 days after the surgery.
Shake can prior to each use. Apply a thin layer of ZORYVE foam, 0.3%, once daily to affected areas on skin and/or scalp when they are not wet. Rub in completely.

Wash hands after application.

Avoid fire, flame, and smoking during and immediately following application [see Warnings and Precautions (5.1)].

ZORYVE foam, 0.3%, is for topical use only and not for ophthalmic, oral, or intravaginal use.
A suppository base comprises a water insoluble base e.g. one or more fatty acid glycerides and a pharmaceutically acceptable gel forming soap in a quantity such that the viscosity of the composition at its casting temperature is about 100 centipoises, the composition being solid as temperatures below 25 DEG C. and softenable at normal human body temperatures.  The preferred glycerides are those of saturated C12-C18 fatty acids. The preferred soaps are aluminium soaps of long chain fatty acids especially aluminium mono- and di-stearate.  They are used in quantities of 0,5 to 3,0, and preferably 2% based on the glyceride.  The soap is dissolved in an organic solvent such as chloroform, petroleum ether or benzene, added to the melted glycaride, the solvent removed and one or more solid medicaments e.g. bismuth subnitrate or subgallate incorporated therein, cast into suppository moulds and allowed to set.  Specification 694,970 is referred to.
Angiogenesis is the formation of new blood vessels. Angiogenesis is driven by cytokines including vascular endothelial growth factor. Tivozanib is an oral medication that inhibits vascular endothelial growth factor preventing tumor from developing new blood vessels.

The purpose of this study is to evaluate the effects of tivozanib on hepatocellular (liver) cancer. Participants in the study take tivozanib daily at a dose of 1 mg for 1month. if doing well the dose would be increased to 1.5 mg per day. Patients are monitored for response using CT or MRI scans every 2months. In addition, patients will have blood draws to evaluate the effects of tivozanib on blood vessels.
Summary/AbstractMiddle meningeal artery embolization has become an important treatment option for chronic subdural hematomas. While the treatment is safe, we present a unique case of development of an iatrogenic middle meningeal artery pseudoaneurysm during endovascular embolization with use of a dual-lumen balloon catheter used for injection of a liquid embolic agent. A 62-year-old man on Coumadin for portal vein thrombosis presented to the hospital with headache and supratherapeutic INR. Imaging revealed bilateral acute on chronic subdural hematomas. Given his medical comorbidities he underwent endovascular middle meningeal artery embolization. During the embolization, angiography revealed a pseudoaneurysm of the middle meningeal artery related to use of a dual-lumen balloon catheter. This pseudoaneurysm was successfully treated with ethylene vinyl alcohol embolization. Intracranial pseudoaneurysm related to balloon catheter use is a rare cause of iatrogenic pseudoaneurysm and could lead to life-threatening intracranial bleeding. Therefore, recognition and timely treatment are important.
Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
The addition of molecules or growth factors to the implant surface is an approach to enhance bone to implant contact (BIC).1 Platelet rich fibrin matrix (PRFM) is an autologous concentrated platelet-rich thrombin free fibrin matrix, prepared by two step centrifugation of blood. Platelets isolated, remain intact and retain their growth factor compliment. This allows a more effective, sustained release of growth factors to the wound site following PRFM application.2 During the second spin, a cross-linking of fibrin takes place, resulting in the formation of a dense fibrin matrix, within which a concentration of viable platelets can be found. Having an organized fibrin matrix at the start of healing accelerates the speed of vascular ingress into the wound compared to non-accelerated healing, which requires a longer time for fibrin formation and the development of vascularity. The earlier the vascularity is established, faster is the migration of the bone-forming cells at the wound site and initiation of bone formation. Therapeutic applications of platelet-rich products have led to improved bone regeneration and faster titanium implant osseointegration, which improve the stability and maintenance of dental implants by increasing BIC.1 Mesenchymal stem cells (MSCs) is a multipotent stromal cell with prominent regenerative functions. MSCs were first identified and isolated from bone marrow and then found in various tissues including umbilical cord, adipose tissue and peripheral blood. Among these sources peripheral blood MSCs draw increasing attention as they share similar biological characteristics with MSCs derived from bone marrow or adipose tissue. Bone marrow derived mesenchymal stem cells(BMMSCs) are multipotent cells capable of differentiating into osteoblasts, chondrocytes, adipocytes , fibroblasts, tenocytes, and myoblasts , which are considered as a cell source for various tissue repair and regenerating bone defects.3 The requirements of aspiration of bone marrow from the patient will cause pain and morbidity of the donor sites. It will be very convenient if peripheral blood mesenchymal stem cells (PBMSCs) could be harvested and expanded to enough numbers, with their osteogenic capacity maintained in a clinical permitted period.

The literature search does not show any human clinical trial conducted till date to assess the regenerative potential of this new modality i.e. PRFM and peripheral blood mesenchymal stem cells. This study therefore aims at the evaluation of PRFM and PBMSCs as regenerative materials for implant stability.
The Precision Medicine Initiative was launched upon the potential of genomic information to tailor medical care. Cascade genetic testing represents a powerful application of precision medicine and involves the process of familial diffusion or the "cascade" of genomic risk information. When an individual (proband) is found to carry a cancer-associated germline pathogenic mutation, the information should be cascaded or shared with at-risk relatives. First degree relatives have a 50% likelihood of carrying the same cancer-associated mutation. This process of cascade testing offers at-risk relatives the opportunity for genetic testing and, for those who also carry the cancer-associated mutation, genetically targeted primary disease prevention through intensive cancer surveillance, chemoprevention and risk-reducing surgery, reducing morbidity and preventing mortality. Cascade testing has been designated by the Centers for Disease Control and Prevention as a Tier 1 genomic application for hereditary breast and ovarian cancer. In this manuscript we describe a cascade genetic testing and in particular focus on its potential to provide necessary care to medically underserved and vulnerable populations.
Hypertension is a common condition, with an estimated prevalence around 20 percent in Canada. It is a major risk factor for cardiovascular disease. Recently, Hypertension Canada has updated its guidelines and recommend we should consider a 120 mm Hg systolic blood pressure target in high-risk patients aged 50 years or older. This recommendation derives mainly from the SPRINT trial. In this trial, blood pressure was measured with an automated oscillometric blood pressure (AOBP) device, the Omron HEM-907 (Omron Healthcare). However, it is not known if measurements performed with this device in a clinical setting are equivalent to those made in a research setting. Therefore, this randomized-controlled trial was designed. It aims to compare the blood pressure measurements of 70 patients in a clinical and a research setting. Patients will be randomized to a clinical/research or a research/clinical sequence.
PURPOSE:To provide a medicinal chewing gum prolonging the retention time of a medicine in the mouth and exhibiting improved drug action to mitigate the inflammation caused by cold, etc., by mixing a chewing gum with a medicine having analgesic, antitussive, expectorant and anti-inflammatory activities. CONSTITUTION:A chewing gum for candy is mixed with a medicine having analgesic, antitussive, expectorant and anti-inflammatory activities. Concretely, a chewing gum is imparted with fungicidal effect by the addition of cetyl pyridinium chloride and KIKYO (root of Platycodon grandiflorum) extract or an anti-inflammatory chewing gum is produced by a chewing gum with NINJIN (root of Panax ginseng) extract, KIKYO extract, TOKON (root of Cephaelis ipecacuanha) extract and MAO (stalk of Ephedra sinica) extract. The retention time of the medicine in the mouth can be extended by the chewing gum to enable the exposed of the mucosa of throat with a medicine having a specific concentration or above for a long period. A definite retaining time in the mouth can be assured even for a child. The chewing gum can be easily produced.
The invention belongs to the field of edible fungi, and particularly discloses a Pleurotus geesteranus (Pleurotus pulmonarius) strain Qian Xiu No. 3 with a preservation number of CCTCC NO: M20211210. The invention also discloses the application of the strain in the aspects of food, health-care products or beverages and the like. The pileus of the strain Qian Xiu No. 3 is light brown, plump and high in commodity value; secondly, the cultivation period is short, and the production period of the Guizhou mushroom No. 3 is at least 15-20 days shorter than that of the existing Pleurotus geesteranus main cultivated variety; in addition, Qian Xiu No. 3 has high yield, the average yield per bag is 352.3g, and the economic benefit is high. The invention also discloses a molecular marker with specificity to the strain, and the molecular marker is used for identifying Guizhou Xiu No. 3, so that the result is accurate and reliable; the detection method is simple and fast; is suitable for on-site or real-time detection in authenticity or infringement authentication of Guizhou province No. 3.
The mothers were provided with a three-day training consisting of six sessions. Two sessions were held each day, with each session lasting for 30 minutes.